4-氨基-2-溴苯甲酸甲酯 | 98545-64-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氨基-2-溴苯甲酸甲酯
• 英文名称: methyl 4-amino-2-bromobenzoate
• 英文别名: 4-amino-2-bromobenzoic acid methyl ester；methyl-2-bromo-4-aminobenzoate
• CAS: 98545-64-3
• 化学式: C₈H₈BrNO₂
• mdl: MFCD00859376
• 分子量: 230.061
• InChiKey: KZOQVTUWEHNNMH-UHFFFAOYSA-N

物化性质

• 熔点：
  94 °C
• 沸点：
  345.2±22.0 °C(Predicted)
• 密度：
  1.578±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  存储条件：室温、密闭保存，并保持干燥。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 4-amino-2-bromobenzoate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 4-amino-2-bromobenzoate
CAS number: 98545-64-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H8BrNO2
Molecular weight: 230.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氨基-2-溴苯甲酸甲酯 在 硫酸 、 sodium nitrite 作用下， 以 水 为溶剂， 反应 6.0h， 以41.1%的产率得到2-溴-4-羟基苯甲酸甲酯
  参考文献：
  名称：

  基于1,2-二苯乙炔骨架的两亲性α-螺旋模拟物

  摘要：

  为了模拟两亲性α-螺旋，设计了一种基于1,2-二苯基乙炔的新型支架。NMR和计算模型证实，分子内氢键有利于1,2-二苯乙炔的构象，从而可以精确模拟在α-螺旋相对表面上发现的i，i + 7和i + 2，i + 5侧链。 。

  DOI：

  10.1021/ol401197n
• 作为产物：
  描述：

  2-溴-4-硝基苯甲酸 在 氯化亚砜 、 tin(II) chloride dihdyrate 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 反应 22.0h， 生成 4-氨基-2-溴苯甲酸甲酯
  参考文献：
  名称：

  时间活检细菌中硝基还原酶的可激活镧系元素发光探针。

  摘要：

  在本文中，我们报道了用于活细菌中硝化还原酶（NTRs）的时间门控检测的镧系元素发光探针的开发。该探针通过NTR诱导的敏化卡丁酰触角的形成并导致能量转移到镧系元素中心而被激活。这种新颖的NTR响应触发器实际上是非荧光的灭活形式，并且在激活时具有大的信号增强功能。我们显示该探针能够在裂解液以及ESKAPE家族的活细菌中选择性检测NTR，ESKAPE家族的活细菌是临床上高度相关的多抗性病原体，负责大多数医院感染。结果表明，我们的探针可用于开发细菌感染的诊断工具。

  DOI：

  10.1002/anie.202002391

文献信息

• Tricyclic benzazepine vasopressin antagonists
  申请人：American Cyanamid Company

  公开号：US05753648A1

  公开（公告）日：1998-05-19

  Tricyclic compound of the general Formula I: ##STR1## as defined herein which exhibit antagonist activity at V.sub.1 and/or V.sub.2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and process for preparing such compounds.

  三环化合物的一般公式I：##STR1##，如本文所述，具有V.sub.1和/或V.sub.2受体的拮抗剂活性，并在体内表现出抗利尿激素拮抗剂活性，使用这些化合物治疗以肾水过度重吸收为特征的疾病的方法，以及制备这些化合物的方法。
• [EN] NOVEL IMIDAZOPYRAZINE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS D'IMIDAZOPYRAZINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2021249896A1

  公开（公告）日：2021-12-16

  The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein Rx and R3 to R5 are as described herein (formula (I)) or pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

  这项发明提供了具有一般式(I)的新型咪唑吡嗪衍生物，其中Rx和R3至R5如本文所述（式(I)）或其药学上可接受的盐。还提供了包括这些化合物的药物组合物、制造这些化合物的方法以及将这些化合物用作药物的方法，特别是将这些化合物用作抗生素治疗或预防细菌感染及由此导致的疾病的方法。
• [EN] BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS AND USES THEREOF<br/>[FR] ACIDES BÊTA-AMINÉS SUBSTITUÉS EN BÊTA ET ANALOGUES À UTILISER EN TANT QU'AGENTS DE CHIMIOTHÉRAPIE ET LEURS UTILISATIONS
  申请人：QUADRIGA BIOSCIENCES INC

  公开号：WO2017024009A1

  公开（公告）日：2017-02-09

  β-Substituted β-amino acids, β-substituted β-amino acid derivatives, and β-substituted β-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.

  β-取代β-氨基酸，β-取代β-氨基酸衍生物，β-取代β-氨基酸类似物和（生物）同位素以及它们作为化疗药物的用途被披露。β-取代β-氨基酸衍生物和β-取代β-氨基酸类似物和（生物）同位素是选择性LAT1/4F2hc底物，并在表达LAT1/4F2hc转运蛋白的肿瘤中表现出快速摄取和保留。还披露了合成β-取代β-氨基酸衍生物和β-取代β-氨基酸类似物的方法以及使用这些化合物治疗癌症的方法。β-取代β-氨基酸衍生物和β-取代β-氨基酸类似物在表达LAT1/4F2hc转运蛋白的肿瘤细胞中表现出选择性摄取，并在体内给予受试者后在癌细胞中积累。β-取代β-氨基酸衍生物和β-取代β-氨基酸类似物和（生物）同位素对几种肿瘤类型表现出细胞毒性。
• [EN] INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD)<br/>[FR] COMPOSÉS INDOLIQUES OU ANALOGUES DE CEUX-CI UTILES DANS LE TRAITEMENT DE LA DÉGÉNÉRESCENCE MACULAIRE LIÉE À L'ÂGE (DMLA)
  申请人：NOVARTIS AG

  公开号：WO2012093101A1

  公开（公告）日：2012-07-12

  The present invention provides a compound of formula (I): a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种公式(I)的化合物：一种制造本发明化合物的方法及其治疗用途。本发明进一步提供了一种药物活性剂的组合物和一种药物组合物。
• Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer
  作者：Ao Wang、Yawan Wang、Xin Meng、Yushe Yang

  DOI：10.1016/j.bmc.2020.115953

  日期：2021.2

  Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3–fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c

  前列腺癌 (PC) 是全球男性最常见的恶性肿瘤。在这里，设计并合成了作为强效雄激素受体 (AR) 拮抗剂的恩杂鲁胺的两个系列新型硫乙内酰脲衍生物。其中，化合物31c被鉴定为 AR 拮抗剂，其效力是 enzalutamide 的 2.3 倍。进行了分子对接研究以解释31c在 AR 上的增强效力。在细胞增殖试验中，31c与恩杂鲁胺对激素敏感的 LNCaP 细胞和 AR 过表达的 LNCaP/AR 细胞表现出类似的抗增殖活性。这些数据表明，31c可以成为用于治疗前列腺癌的进一步结构优化的良好先导化合物。